Thought deceleration + MXiPr
MXiPr is known to produce thought deceleration, a cognitive effect. The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into slow motion. Internal dialogue becomes sparse and sluggish, with each idea taking longer to form and process, producing a sense of mental heaviness or cognitive inertia.
About Thought deceleration
Thought deceleration is experienced as a conspicuous slowing of one's internal mental processes. From a first-person perspective, it feels as though the mind is wading through thick fluid — ideas form slowly, connections take longer to make, and the internal monologue may become halting or sparse. Tasks that normally require quick thinking, such as following a conversation or doing mental arithmetic, become noticeably more effortful. There is often a sense of mental fog or heaviness, as though the cognitive machinery is operating at reduced power.
The intensity of thought deceleration exists on a spectrum. At mild levels, it manifests as a gentle slowing that may actually feel pleasant — a quieting of the mental chatter that can produce relaxation or meditative calm. At moderate levels, the slowing becomes more pronounced and potentially frustrating, as one struggles to complete thoughts or maintain a conversational thread. At high intensities, thought deceleration can feel profoundly impairing: the mind may generate only a few fragmented ideas per minute, and there may be extended periods of mental blankness. At extreme levels, subjective mental activity can slow to a near standstill.
Several variations of this effect exist. Serene deceleration involves a peaceful, almost meditative slowing that feels restful and welcome. Foggy deceleration is characterized by confusion and disorientation alongside the reduced speed. Heavy deceleration carries a sense of cognitive weight or gravity, as if thoughts are physically burdened. Intermittent deceleration involves periods of normal-speed thinking punctuated by sudden episodes of dramatic slowing, which can be disorienting.
Pharmacologically, thought deceleration results from enhanced inhibitory neurotransmission or reduced excitatory signaling. GABAergic substances (benzodiazepines, alcohol, barbiturates) achieve this by potentiating inhibitory GABA-A receptor activity, dampening cortical excitability. Opioids produce deceleration through mu-receptor activation and secondary effects on noradrenergic signaling. Cannabis can produce thought deceleration through CB1 receptor activation in the prefrontal cortex, disrupting working memory and executive function. Some dissociatives produce deceleration through NMDA receptor antagonism, which reduces glutamatergic excitatory transmission.
This effect is most commonly associated with depressant substances including benzodiazepines, alcohol, opioids, and barbiturates. Cannabis frequently produces thought deceleration, particularly indica-dominant strains and edible preparations. Antihistamines, muscle relaxants, and antipsychotics can also produce this effect. Some psychedelics may produce transient thought deceleration during the comedown phase, and high doses of dissociatives commonly produce profound cognitive slowing.
Thought deceleration becomes a safety concern when it impairs judgment and reaction time. Driving or operating machinery under the influence of substances that produce this effect is dangerous. The effect can mask the severity of intoxication — a person may not realize how impaired they are precisely because their thinking is too slow to accurately self-assess. Combining multiple depressants dramatically amplifies thought deceleration and can progress to dangerous levels of sedation or loss of consciousness. In medical contexts, sudden onset of thought deceleration without substance use can indicate neurological issues and should prompt medical evaluation.